OOIR: Observatory of International Research

Papers

(The H4-Index of ESC Heart Failure is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Heart failure after myocardial infarction: incidence and predictors	289
Machine learning vs. conventional statistical models for predicting heart failure readmission and mortality	101
Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives	94
Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis	85
Sarcopenia in heart failure: a systematic review and meta‐analysis	82
Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock	79
Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic	74
Cardiogenic shock teams and centres: a contemporary review of multidisciplinary care for cardiogenic shock	61
Iron deficiency in heart failure	55
Heart failure in the last year: progress and perspective	55
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data	55
SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials	53
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial	52
‘Time is prognosis’ in heart failure: time‐to‐treatment initiation as a modifiable risk factor	50
Reaching consensus for unified medical language in Fontan care	50
Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic	48
Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction	47
Hospital readmissions of patients with heart failure from real world: timing and associated risk factors	47
Heart failure related to adult congenital heart disease: prevalence, outcome and risk factors	40
Cardiac performance in patients hospitalized with COVID‐19: a 6 month follow‐up study	39
Heart failure: an update from the last years and a look at the near future	37
Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care	36
Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes	36
Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry	36
Heart failure is associated with an increased incidence of cancer diagnoses	34

Fibrosis‐4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction	34
Real‐world evidence in a national health service: results of the UK CardioMEMS HF System Post‐Market Study	34
Thromboembolism and bleeding in systemic amyloidosis: a review	34
Early use of remote dielectric sensing after hospitalization to reduce heart failure readmissions	34
Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature	33
Blood urea nitrogen to serum albumin ratio as a new prognostic indicator in critical patients with chronic heart failure	33
Sacubitril/valsartan in real‐life European patients with heart failure and reduced ejection fraction: a systematic review and meta‐analysis	33
A year in heart failure: an update of recent findings	33